The Antibiotics Exist —The System Cannot Deliver Them
This is not a discovery problem. It is a market entry and access problem, and it is far more tractable than the pipeline crisis we spend most of our attention on.
This is not a discovery problem. It is a market entry and access problem, and it is far more tractable than the pipeline crisis we spend most of our attention on.
Medicare policy should be transparent and include appropriate notice and stakeholder input. And when a contractor gets it wrong, there should be a clear and rapid way to stop the harm to patients, their relationship with their doctor and the doctor’s practice.
Patients obtaining drugs through social media, medical spas, or telehealth platforms are not the same as patients obtaining drugs through more traditional illicit channels because they often believe what they are receiving is a clinically validated product. This means they may present with unexplained symptoms without realizing their online purchase is even relevant to the conversation
As a country, we have developed treatments capable of improving the quality of life and preventing long-term damage for children with rheumatic conditions, yet many children cannot obtain them when they need them most. This needs to change.
Healthcare has a habit of embracing patient empowerment right up until patients become powerful.
The Centers for Medicare & Medicaid Services (CMS) took constructive steps in its 2027 final rule and rate announcement, particularly on payment integrity and quality measurement. But those steps are not the finish line. Policymakers should further modernize MA to strengthen competition, transparency and accountability. Here’s where to start.
They see the problem first, build the fix, and decide whether it is ever adopted. The market has trained them to hide the one credential that de-risks the deal.
Why the flood of consumer wellness devices demands clear boundaries between lifestyle improvement and clinical diagnostics
The next healthcare revolution isn't about treating osteoporosis, it's about preserving mobility and healthspan.
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is that not only is this terrible for patient health, it can be more costly in the end.
A letter to Medicaid Directors, State Leaders, and other invested collaborators who were awarded Rural Health Transformation (RHT) Grant funding.
The policy conversation needs to shift from just deprescribing alone to building the clinical infrastructure that delivers consistent, high-quality behavioral health care.
For years, the healthcare industry treated data collection as the main challenge. The next phase is about interpretation, coordination, and operational usability.
If we want more nurses, we need more nursing students, which means creating the educational infrastructure needed to help them succeed.
Patients, providers, and innovators all benefit from secure, trusted, nationwide data exchange. But this trust cannot sustain itself on fragmented governance or competitive enforcement dynamics.